Musings from The Power List: Renee Aguiar-Lucander
Renee Aguiar-Lucander argues that faster clinical trials and more pragmatic regulation are essential to bringing medicines to patients sooner
Clinical Scorecard: Musings from The Power List: Renee Aguiar-Lucander
At a Glance
| Category | Detail |
|---|
| Condition | Drug Development |
| Key Mechanisms | Regulatory processes, clinical trial management, real-world evidence utilization |
| Target Population | Patients requiring new therapies, particularly in rare diseases |
| Care Setting | Pharmaceutical industry |
Key Highlights
- Successful Phase 3 study with high statistical significance (p < 0.0001)
- Need for improved oversight in clinical trials and regulatory processes
- Advocacy for real-world evidence in drug development
- Expectation of reduced regulatory review times in the future
- Importance of transparency and value in healthcare
Guideline-Based Recommendations
Diagnosis
Management
- Reduce regulatory focus on randomized trials in early phases for rare diseases
- Utilize real-world evidence more effectively
Monitoring & Follow-up
Risks
- Conservatism and preference for written responses in regulatory decision-making
Patient & Prescribing Data
Patients with rare diseases and those in need of new therapies
Emphasis on the value of medicines relative to healthcare costs
Clinical Best Practices
- Improve clinical trial timelines and patient recruitment strategies
- Enhance oversight of contract research organizations
- Expand geographically into lower-priced markets
Related Resources & Content
